Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy.

Unexpectedly, in our study, patients who had the shortest WP 0-30 days had the most disease activity. Shortening WPs may not be enough to suppress disease activity post-natalizumab switch.